Who makes Hydromorphone 100mcg?

Hydromorphone 100mcg is developed by Brigham and Women's Hospital.

What development phase is Hydromorphone 100mcg in?

Hydromorphone 100mcg is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Hydromorphone 100mcg

Brigham and Women's Hospital · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Hydromorphone 100mcg
Also known as	HM100
Sponsor	Brigham and Women's Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids (PHASE4)
Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hydromorphone 100mcg CI brief — competitive landscape report
Hydromorphone 100mcg updates RSS · CI watch RSS
Brigham and Women's Hospital portfolio CI